ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...
TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.
Alternatively, if you have lower amounts of the HER2 protein, your cancer is HER2 negative. And your doctor will prescribe a different course of treatment. Treatments for both HER2 positive and ...
Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...
Clinical Trials Arena on MSN3d
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patientsPharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...
With the average age for women to be diagnosed with breast cancer is late forties, one woman revealed she was diagnosed with ...
A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.
The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...
New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback